RSC Pharmaceutics最新文献

{"title":"Personalized medicine: a quality by design approach to printable tablet production†","authors":"Thomas P. Forbes, Olivia Agolini, Zainab Altamimi and Jeffrey Lawrence","doi":"10.1039/D5PM00041F","DOIUrl":"https://doi.org/10.1039/D5PM00041F","url":null,"abstract":"<p >The versatility afforded by emerging additive manufacturing technologies (<em>e.g.</em>, 3D printing and precision drop-on-demand deposition) has enabled the rapid and agile production of personalized medicine. The on-demand customization capabilities of these technologies provide novel avenues for point-of-care or distributed pharmaceutical manufacturing and compounding applications. Quality by design principles were used to investigate the production of solid tablet dosage forms for narrow therapeutic index (warfarin), selective serotonin reuptake inhibitor (citalopram), and medical countermeasure (doxycycline) drugs. We examined critical material attributes, critical process parameters, and critical quality attributes for the semisolid extrusion of pharmaceutical tablet excipients and drop-on-demand active pharmaceutical ingredient (API) ink dosing. Detailed investigations optimized the API ink formulation – specifically fluid properties relative to the tablet semisolid excipient, excipient temperature and physical state (<em>i.e.</em>, solid <em>vs.</em> liquid), and solidification time – allowing for API and excipient mixing and redistribution. Personalized drug dosages, adjusted doses, and tapered regimens were manufactured, demonstrating accurate API quantity and required production content uniformity, as specified by the U.S. Pharmacopeia. Atline API ink verification and inline drop counting control strategies were employed and confirmed by post-production quantification measurements to properly maintain tablet-to-tablet quality assurance.</p>","PeriodicalId":101141,"journal":{"name":"RSC Pharmaceutics","volume":" 5","pages":" 1096-1109"},"PeriodicalIF":0.0,"publicationDate":"2025-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://pubs.rsc.org/en/content/articlepdf/2025/pm/d5pm00041f?page=search","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145073543","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Breaking the cellular delivery bottleneck: recent developments in direct cytosolic delivery of biologics","authors":"Harini Nagaraj, Victor Lehot, Nourina Nasim, Yagiz Anil Cicek, Ritabrita Goswami, Taewon Jeon and Vincent M. Rotello","doi":"10.1039/D5PM00129C","DOIUrl":"10.1039/D5PM00129C","url":null,"abstract":"<p >Proteins and nucleic acid therapeutics represent a significant and growing share of the pharmaceutical landscape. The majority of biological and therapeutic applications of these biomolecules require access to the cytosol. Delivery of biologics directly to the cytosol is made difficult by the impermeability of the cell membrane. As a result, most delivery strategies have utilized endocytic uptake pathways to deliver biologics into the cell. However, endosomally entrapped cargo often faces limited escape efficiency and is prone to degradation within endo/lysosomal compartments. The emergence of delivery vehicles capable of bypassing endocytosis and directly traversing the cell membrane offers a promising approach to improve the cytosolic delivery efficiency of biomolecules. Here, we highlight recent developments in endocytosis-independent delivery systems for biologics and ways to accurately assess cytosolic delivery of biologics. Strategies employing covalent and non-covalent modification of biomolecules will be reviewed, along with strategies incorporating both covalent and supramolecular processes.</p>","PeriodicalId":101141,"journal":{"name":"RSC Pharmaceutics","volume":" 5","pages":" 850-864"},"PeriodicalIF":0.0,"publicationDate":"2025-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12230783/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144602751","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advances in targeted therapies and emerging strategies for blood cancer treatment","authors":"Samson A. Adeyemi, Lindokuhle M. Ngema and Yahya E. Choonara","doi":"10.1039/D5PM00090D","DOIUrl":"https://doi.org/10.1039/D5PM00090D","url":null,"abstract":"<p >Blood cancers, including leukemia, lymphoma, and multiple myeloma, originate within the bone marrow, where the intricate microenvironment presents considerable challenges for conventional therapies such as chemotherapy, immunotherapy, radiotherapy, and hematopoietic stem cell transplantation. These approaches often suffer from poor specificity, low bioavailability, and systemic toxicity, resulting in suboptimal treatment outcomes. In response, significant advances in targeted drug delivery systems, including liposomes, pegylated formulations, and polymeric nanoparticles have been developed to enhance drug stability, prolong circulation time, and improve tumor accumulation while reducing off-target effects. This review provides a comprehensive overview of recent innovations in ligand-directed drug delivery systems for blood cancers. Emphasis is placed on systems functionalized with antibodies, peptides, aptamers, and proteins designed to overcome the barriers of the bone marrow niche and enable selective delivery to malignant cells. Notably, leukemia has emerged as a key model for evaluating these technologies, with promising preclinical and clinical results. However, despite technological progress, critical translational challenges remain. These include biological heterogeneity, variability in target receptor expression, immunogenicity of nanoparticles, and the complexity of scaling multifunctional delivery systems under clinical conditions. Furthermore, current <em>in vitro</em> and <em>in vivo</em> models fail to accurately recapitulate the bone marrow's dynamic physiology, underscoring the need for improved predictive systems. Future perspectives suggest the integration of personalized nanomedicine approaches that adapt to patient-specific genetic profiles and disease states. Additionally, artificial intelligence (AI) and big data analytics are expected to revolutionize delivery optimization, biomarker discovery, and therapy customization. Ultimately, interdisciplinary collaboration is required to bridge the gap between bench and bedside. By addressing current limitations and embracing innovation, the field moves closer to realizing safe, precise, and effective therapies for patients with hematologic malignancies.</p>","PeriodicalId":101141,"journal":{"name":"RSC Pharmaceutics","volume":" 5","pages":" 950-961"},"PeriodicalIF":0.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://pubs.rsc.org/en/content/articlepdf/2025/pm/d5pm00090d?page=search","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145073491","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Biocompatible ionic liquid-based nanoparticles for effective skin penetration and intracellular uptake of antisense oligonucleotides†","authors":"Kiyohiro Toyofuku, Rie Wakabayashi, Yoshirou Kawaguchi, Noriho Kamiya and Masahiro Goto","doi":"10.1039/D5PM00087D","DOIUrl":"https://doi.org/10.1039/D5PM00087D","url":null,"abstract":"<p >A novel formulation (IL-NP) for the transdermal delivery of nucleic acid medicines was developed using biocompatible ionic liquid (IL). The formulation was created by mixing DNA in water with an IL in ethanol, followed by freeze-drying and dispersion in oil, producing uniformly sized particles. <em>In vitro</em> studies demonstrated the enhanced skin penetration of IL-NP, while mechanistic studies showed that the IL increased cell membrane fluidity to promote cellular uptake. <em>In vivo</em> experiments with tumor-bearing mice confirmed that transdermal administration of IL-NP achieved comparable antitumor effects as direct injection of DNA, without side effects. This formulation effectively overcomes barriers to both stratum corneum penetration and cellular uptake, providing a non-invasive alternative to injecting nucleic acid therapeutics.</p>","PeriodicalId":101141,"journal":{"name":"RSC Pharmaceutics","volume":" 5","pages":" 1078-1086"},"PeriodicalIF":0.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://pubs.rsc.org/en/content/articlepdf/2025/pm/d5pm00087d?page=search","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145073541","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nanosensors in healthcare: transforming real-time monitoring and disease management with cutting-edge nanotechnology","authors":"Shikha Gulati, Rakshita Yadav, Varsha Kumari, Shivangi Nair, Chetna Gupta and Meenal Aishwari","doi":"10.1039/D5PM00125K","DOIUrl":"https://doi.org/10.1039/D5PM00125K","url":null,"abstract":"<p >The field of healthcare monitoring continuously strives to find new and better ways of improving healthcare access and advancing the accuracy and precision of diagnostic and treatment approaches. To add to its challenges, the modern and fast-paced lifestyle now presents the need for even more sensitive, specific, and rapid methods of continuous healthcare monitoring technology that can generate real-time information. The integration of cutting-edge nanotechnology in health care with its unique and versatile properties has brought a technological revolution in the way disease detection, management, and treatment are approached, finding applications from early-stage disease detection to real-time physiological parameter monitoring. The unique physical and chemical properties of nanoparticles provide a basic structural framework on which successive chemical and biological detection systems can be built. This characteristic of nanoparticles provided healthcare researchers with opportunities to create nanoparticle-based nanosensors, nanomedicine, bioimaging, point-of-care, and other such devices. Here we provide a comprehensive review of the development and advancement of nanosensors in healthcare monitoring, its types, applications, and future prospects, and highlight the development and challenges faced in the field. The review also sheds light on the all-encompassing nature of nanotechnology, in terms of compatibility with different existing streams of applied sciences in healthcare.</p>","PeriodicalId":101141,"journal":{"name":"RSC Pharmaceutics","volume":" 5","pages":" 1003-1018"},"PeriodicalIF":0.0,"publicationDate":"2025-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://pubs.rsc.org/en/content/articlepdf/2025/pm/d5pm00125k?page=search","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145073570","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Solid lipid nanoparticles in cervical cancer: a comprehensive review of a decade of progress and prospects","authors":"Pooja Tiwary, Krishil Oswal, Ryan Varghese, Ravi Vamsi Peri and Pardeep Gupta","doi":"10.1039/D5PM00109A","DOIUrl":"https://doi.org/10.1039/D5PM00109A","url":null,"abstract":"<p > <em>Background</em>: Cervical cancer is the second most commonly diagnosed cancer worldwide and the third leading cause of death among women, with approximately 604 127 new cases being reported in 2020. Conventional treatment methods, such as chemotherapy, radiation therapy, surgery, and hormonal therapy, often face significant challenges, including systemic toxicity and reduced efficacy, particularly in the advanced stages of the disease. The treatment of cervical cancer is further complicated by tumor heterogeneity, resistance mechanisms to chemotherapeutic drugs, and the persistent presence of HPV. However, in recent years, nanotechnological interventions, particularly solid lipid nanoparticles (SLNs), have gained increasing attention owing to their robust potential to effectively deliver chemotherapeutic agents while minimizing systemic toxicity. SLNs present a compelling solution for reducing side effects, enhancing drug solubility, improving stability and bioavailability, and overcoming the limitations and resistance associated with conventional treatment strategies. <em>Methods</em>: To provide the context and evidence, relevant publications were searched on Google Scholar, PubMed, ScienceDirect, Dimensions AI, and EBSCO host, using specific keywords such as “cervical cancer”, “drug loading”, “encapsulation efficiency”, “HPV”, “sustained drug release”, and “solid lipid nanoparticles (SLNs)”. We did not impose any restrictions on the publication date during the selection of papers. However, it is imperative to highlight that the initial reports containing specified keywords began publication in 2013. <em>Conclusion</em>: SLNs represent a promising frontier in drug delivery, particularly within cervical cancer therapeutics, because of their ability to facilitate the targeted delivery of chemotherapeutic agents and genetic materials. The potential of SLNs to encapsulate and protect vital therapeutic compounds presents significant opportunities for developing innovative treatment strategies including DNA and peptide vaccines. However, the lack of approved SLN-encapsulated vaccines for cervical cancer underscores the need for rigorous <em>in vivo</em> research and clinical trials to validate their safety and efficacy. Future studies should not only optimize SLNs for various agents but also explore diverse combination therapies to enhance therapeutic outcomes.</p>","PeriodicalId":101141,"journal":{"name":"RSC Pharmaceutics","volume":" 5","pages":" 930-949"},"PeriodicalIF":0.0,"publicationDate":"2025-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://pubs.rsc.org/en/content/articlepdf/2025/pm/d5pm00109a?page=search","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145073490","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Phenylboronic acid derivatives: advancing glucose-responsive insulin delivery and multifunctional biomedical applications","authors":"Kofi Oti Boakye-Yiadom, Debmalya Roy, Hajra Zafar and Faisal Raza","doi":"10.1039/D5PM00083A","DOIUrl":"https://doi.org/10.1039/D5PM00083A","url":null,"abstract":"<p >Phenylboronic acid (PBA) and its derivatives have emerged as versatile materials with significant implications in biomedical and industrial applications, particularly for glucose-responsive systems. Their unique saccharide-binding properties, dictated by their tunable p<em>K</em><small>_a</small>, enable advanced functionalities in drug delivery and biosensing. In diabetes management, PBA-based systems ranging from bulk hydrogels to micro/nanogels and self-assembled micelles offer precise insulin delivery mechanisms that respond dynamically to glucose levels. These materials are further enhanced by their adaptability to diverse routes of administration, including subcutaneous, transdermal, and oral delivery systems. Beyond insulin delivery, multifunctional PBA derivatives combined with glucose oxidase or polymers have been utilized in diabetic wound healing, biosensing, and environment-sensitive therapeutic applications like siRNA and cancer immunotherapy. The integration of PBA into hybrid and dual-responsive platforms continues to expand its utility, paving the way for innovative solutions in personalized medicine and diagnostics. This review explores the chemistry, applications, and future prospects of PBA derivatives, emphasizing their transformative potential in creating responsive, biocompatible, and multifunctional systems for biomedical use.</p>","PeriodicalId":101141,"journal":{"name":"RSC Pharmaceutics","volume":" 5","pages":" 962-981"},"PeriodicalIF":0.0,"publicationDate":"2025-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://pubs.rsc.org/en/content/articlepdf/2025/pm/d5pm00083a?page=search","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145073492","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Introduction, classification and applications of 3D bioprinted hydrogels for cancer treatment: a review","authors":"Anusha Thumma","doi":"10.1039/D5PM00142K","DOIUrl":"https://doi.org/10.1039/D5PM00142K","url":null,"abstract":"<p >Polymeric hydrogels have become effective materials in cancer therapy because of their biocompatibility, biodegradability and tunable chattels. This review presents a thorough investigation of the synthesis and medicinal uses of different naturally occurring and synthetic hydrogels, for cancer therapy, mainly <em>via</em> 3D modeling and printing. The exceptional biocompatibility of hydrogels, coupled with their remarkable potential for replicating the intricate extracellular matrix (ECM), positions them as ideal materials for constructing scaffolds used in the synthesis of <em>in vitro</em> 3D tumor constructs. Hydrogels can also be used for 3D printing to treat cancer by aiding in accurate control over the composition of hydrogel scaffolds. 3D modeling and printing play an important role in cancer treatment by enabling drug screening. This review distinguishes itself by integrating a comparative analysis of both conventional and emerging hydrogel systems—including natural, synthetic, and hybrid types particularly designed for 3D bioprinting in cancer modeling. This study paves the path for new researchers to explore cancer treatment by combining hydrogel-based materials with advanced techniques.</p>","PeriodicalId":101141,"journal":{"name":"RSC Pharmaceutics","volume":" 5","pages":" 915-929"},"PeriodicalIF":0.0,"publicationDate":"2025-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://pubs.rsc.org/en/content/articlepdf/2025/pm/d5pm00142k?page=search","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145073489","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Babassu oil-based microemulsion promotes uniform in vitro release of diclofenac sodium and donepezil hydrochloride†","authors":"Felipe Schlichta de Gouveia, Gabriela Spingolon and Tanira Alessandra Silveira Aguirre","doi":"10.1039/D5PM00022J","DOIUrl":"https://doi.org/10.1039/D5PM00022J","url":null,"abstract":"<p >Microemulsions are nanostructured and thermodynamically stable systems with a reduced droplet size. They can improve drug absorption and distribution. Babassu oil has been investigated for various therapeutic properties reported by popular use. This work aimed to develop, optimize, and characterize babassu oil-based water-in-oil microemulsions to promote a controlled and uniform release of drugs with different physicochemical properties. The optimal microemulsion composition was investigated through pseudoternary diagrams, with water, surfactant mixture, and oil mixture as vertices. The formulations were characterized based on pH, conductivity, size, polydispersity index, and drug content. <em>In vitro</em> drug release was carried out using multidimensional and unidimensional techniques. An optimum microemulsion contains (w/w): 10% water, 17.8% babassu oil, 26.2% medium-chain triglycerides, 29.7% Span™ 83, 7.1% Tween® 80, and 9.2% Transcutol® HP. Diclofenac sodium (DS), donepezil hydrochloride (DH), and insulin were associated with the dispersed phase of the microemulsion. These formulations presented a droplet size of 26.9 ± 1.9, 22.6 ± 0.4, and 35.5 ± 0.7 nm, respectively. The polydispersity index was &lt;0.1 for all formulations. Microemulsions controlled the outflow of drugs, showing a uniform release compared to the respective controls. It was evidenced that these profiles depend on the features of the molecule associated. According to the selection criteria, most experimental DS and DH release kinetics in water or pH 7.2 fit well with the Gompertz model. In conclusion, a babassu oil-based water-in-oil microemulsion was developed for the first time, optimized, and characterized, supporting further investigation of the formulation as a drug delivery system.</p>","PeriodicalId":101141,"journal":{"name":"RSC Pharmaceutics","volume":" 4","pages":" 824-837"},"PeriodicalIF":0.0,"publicationDate":"2025-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://pubs.rsc.org/en/content/articlepdf/2025/pm/d5pm00022j?page=search","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144624159","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Vascular benefit of the use of mepivacaine as an anaesthetic in resilient hyaluronic acid® injectables","authors":"Jimmy Faivre, Romain Brusini, Jing Jing, Sabrina Walley, Lukas Roubenne, François Bourdon, Lee Walker, Bruno Le Grand and Conor J. Gallagher","doi":"10.1039/D5PM00069F","DOIUrl":"https://doi.org/10.1039/D5PM00069F","url":null,"abstract":"<p >The use of lidocaine (0.3% w/w) for pain management in hyaluronic acid-based soft-tissue injectables has been standard for two decades. Given lidocaine's well-known vasodilatory activity it may contribute to the incidence of post-treatment adverse events including bruising in patients. This study seeks to compare these vasodilatory properties of lidocaine with that of another anaesthetic candidate, mepivacaine. Rat aortic rings and human skin resistance arteries (diameter between 200–400 μm) were mounted on an isolated organ bath or myograph, respectively, and exposed to progressively increasing concentrations of lidocaine or mepivacaine from a solution or released from a gel. The concentration-dependent vascular response and kinetics were systematically compared in tissue originating from 3 biological donors. Additionally, tissue perfusion changes induced by 0.3% w/w anaesthetic solutions were assessed using laser Doppler imaging in rabbit ears. Systematically, lidocaine exhibited a greater vasodilatory activity than mepivacaine in clinically relevant concentration ranges in both animal and human models. In contrast to lidocaine, mepivacaine did not have a significant impact on blood vessel vasodilation. In clinical practice, formulation of hyaluronic acid (HA) injectables with mepivacaine may potentially reduce the risk of common adverse events. This characteristic highlights its potential advantages in the practice of hydrogel injections.</p>","PeriodicalId":101141,"journal":{"name":"RSC Pharmaceutics","volume":" 4","pages":" 814-823"},"PeriodicalIF":0.0,"publicationDate":"2025-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://pubs.rsc.org/en/content/articlepdf/2025/pm/d5pm00069f?page=search","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144624158","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}